Monomethyl Fumarate (MMF, Bafiertam) for the Treatment of Relapsing Forms of Multiple Sclerosis (MS)

MLA

Amnon A Berger, et al. “Monomethyl Fumarate (MMF, Bafiertam) for the Treatment of Relapsing Forms of Multiple Sclerosis (MS).” Neurology International, vol. 13, no. 22, May 2021, pp. 207–23. EBSCOhost, widgets.ebscohost.com/prod/customlink/proxify/proxify.php?count=1&encode=0&proxy=&find_1=&replace_1=&target=https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&scope=site&db=edsair&AN=edsair.doi.dedup.....67248ccd943c9e09cc992b5a5974e69a&authtype=sso&custid=ns315887.

APA

Amnon A Berger, Kevin Berardino, Ivan Urits, Alan D. Kaye, Elyse M. Cornett, Emily R Sottosanti, Ariel Winnick, Omar Viswanath, Giustino Varrassi, & Jonathan Izygon. (2021). Monomethyl Fumarate (MMF, Bafiertam) for the Treatment of Relapsing Forms of Multiple Sclerosis (MS). Neurology International, 13(22), 207–223.

Chicago

Amnon A Berger, Kevin Berardino, Ivan Urits, Alan D. Kaye, Elyse M. Cornett, Emily R Sottosanti, Ariel Winnick, Omar Viswanath, Giustino Varrassi, and Jonathan Izygon. 2021. “Monomethyl Fumarate (MMF, Bafiertam) for the Treatment of Relapsing Forms of Multiple Sclerosis (MS).” Neurology International 13 (22): 207–23. http://widgets.ebscohost.com/prod/customlink/proxify/proxify.php?count=1&encode=0&proxy=&find_1=&replace_1=&target=https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&scope=site&db=edsair&AN=edsair.doi.dedup.....67248ccd943c9e09cc992b5a5974e69a&authtype=sso&custid=ns315887.